CT Head Interpretation in Intracerebral Hemorrhage: ABC/2 Volume, Spot Sign, and Hematoma Expansion

RadiologyNeuroimaging

CT Head Interpretation in Intracerebral Hemorrhage: ABC/2 Volume, Spot Sign, and Hematoma Expansion

A focused interpretive playbook for the acute non-contrast CT and CT angiogram in spontaneous intracerebral hemorrhage. Quantify the bleed in seconds, identify the predictors of expansion, and translate the imaging into the next 60 minutes of management.

Author: gomdori, MDReading time: 14 minUpdated: 2026
~40%30-day mortality (all ICH)
≥30 cm³Volume threshold for poor outcome
50–80 HUAcute hematoma density
~85%Spot sign specificity for expansion

S1Non-contrast CT — Detection & Density

The first-line imaging study in suspected acute intracerebral hemorrhage is a non-contrast CT of the head — fast (60 seconds), universally available, and exquisitely sensitive for fresh blood. Acute clotted hemoglobin attenuates X-rays at 50–80 Hounsfield units (HU) — markedly hyperdense to grey matter (35–45 HU) and white matter (20–30 HU) — appearing as a bright, well-marginated mass.

CT density evolution of intracerebral hemorrhage

PhaseTimeDensity (HU)Appearance
Hyperacute0–6 hours50–80 HUBright homogeneous mass; perilesional edema absent or minimal
Acute6–72 hours60–80 HUBright; perilesional vasogenic edema develops by 24–48 h
Early subacute3–7 days50–60 HUDensity decreases at periphery first; ring of edema enlarges
Late subacute1–3 weeks30–40 HU (isodense)Becomes isodense to brain — easily missed on CT alone; MRI required
Chronic>3 weeks10–30 HU (hypodense)Encephalomalacia, slit-like cavity; hemosiderin rim visible only on MRI GRE/SWI
Caveat — anemia mimics late ICH. In severe anemia (hemoglobin <9 g/dL), acute hematoma may be only moderately hyperdense (35–55 HU) because density correlates with hemoglobin concentration. A relatively low-density “hematoma” in a profoundly anemic patient can be missed or mistaken for tumor. Conversely, polycythemia or contrast staining elevates background density and can mask small bleeds.

Systematic non-contrast CT review (8-step)

  1. Window settings — review brain windows (W:80, L:40) for parenchyma; bone windows for skull fracture; subdural windows (W:160, L:60) for thin extra-axial blood
  2. Hematoma location — basal ganglia, thalamus, cerebellum, pons, lobar; this single feature drives etiology probability
  3. Hematoma volume — apply ABC/2 (Section 2)
  4. Intraventricular extension (IVE) — present in 30–50% of deep ICH; doubles mortality; quantify with Graeb or modified Graeb score
  5. Mass effect — midline shift >5 mm, effacement of perimesencephalic cisterns, uncal herniation, transtentorial herniation
  6. Surrounding edema — vasogenic edema on day 0 suggests subacute or tumor-associated bleed; acute hypertensive ICH typically has minimal early edema
  7. Hydrocephalus — present in 50% of cerebellar and intraventricular bleeds; ventricular index >0.30 or rounded temporal horns
  8. Expansion-predictor signs — irregular shape, swirl sign, black hole sign, blend sign, satellite sign (Section 3)

Distinguishing hemorrhage from mimics

Hyperdensity mimicDistinguishing feature
Cortical contusionMultifocal, peripheral, history of trauma; coup/contrecoup pattern
Hemorrhagic transformation of infarctConforms to vascular territory; petechial or confluent within infarcted tissue
Hemorrhagic tumor metastasisDisproportionate vasogenic edema for hematoma size; multifocal lesions; melanoma/RCC/thyroid/choriocarcinoma history
Cerebral venous sinus thrombosis with venous infarctBilateral parasagittal frontal lobes; cord sign in superior sagittal sinus; empty delta sign on contrast
CalcificationDensity 100–500+ HU (much higher than blood); typical locations (pineal, choroid, basal ganglia)
Iodinated contrast stainingRecent angiography; conforms to gyri; resolves on 24-h follow-up CT (blood does not)

S2ABC/2 Volume Quantification

ABC/2 is a bedside formula that approximates hematoma volume by treating the bleed as an ellipsoid: V = (4/3)π × (A/2) × (B/2) × (C/2), simplified to ≈ A × B × C / 2 when A, B, C are the three orthogonal diameters in centimeters. The formula was validated against planimetric volumetry in the original 1996 study (Kothari et al.) with R² ≈ 0.96, and has been the operational standard since.

Step-by-step ABC/2

AIdentify the CT slice with the largest hematoma cross-section. Measure the longest diameter in cm
BOn the same slice, measure the largest diameter perpendicular to A in cm
CCount the number of slices containing hematoma; multiply by slice thickness (e.g., 5 mm = 0.5 cm) — apply weighting
VMultiply A × B × C, divide by 2 — answer in cm³ (= mL)

Slice weighting for C

For each CT slice with hematoma, count it as 1 (full) if the hematoma area on that slice is ≥75% of the largest cross-section (slice with A and B), 0.5 (half) if 25–75%, and 0 if <25%. Sum the weights and multiply by slice thickness in cm.

Worked exampleCalculation
A (longest diameter on largest slice)5.0 cm
B (perpendicular diameter on same slice)3.5 cm
Slices with hematoma (5 mm thickness)4 full + 2 half = 5 weighted slices × 0.5 cm = 2.5 cm
Volume5.0 × 3.5 × 2.5 / 2 = 21.9 cm³

Volume thresholds and outcome

Volume30-day mortality (supratentorial, untreated)Implication
<10 cm³~10–15%Small bleed; usually managed medically; surveillance imaging at 6–24 h
10–30 cm³~25–40%Moderate bleed; aggressive BP control, ICU monitoring, surgical evaluation if expanding
30–60 cm³~55–70%Large bleed; ICH score ≥1 contribution; surgical evacuation considered case-by-case
>60 cm³>90% (with GCS ≤8)Often unsurvivable; goals-of-care discussion; surgical evacuation rarely beneficial
ABC/2 caveats:
  • Underestimates volume by ~10–20% in irregularly shaped hematomas (which is exactly the shape that predicts expansion)
  • Overestimates in small bleeds <10 cm³ where the ellipsoid assumption fails
  • For surgical decision-making, a planimetric volume from PACS or AI segmentation is more accurate
  • Use the same method for serial measurements to track expansion (do not switch from ABC/2 to planimetric mid-course)
CT Head Interpretation in ICH — Comparison Comparison table: CT Head Interpretation in ICH — Comparison Deep ICH Lobar ICH IVH SAH SDH/EDH Description Basal ganglia, thalamus, internal capsule, brainstem, cerebellum; HTN-related Cortical-subcortical; amyloid angiopathy in elderly Intraventricular extension; worsens prognosis; hydrocephalus Subarachnoid blood; aneurysmal vs traumatic Subdural (crescent) or epidural (lentiform); trauma
CT Head Interpretation in ICH — Comparison

S3CTA Spot Sign & Expansion Predictors

Hematoma expansion — defined as ≥6 cm³ absolute or ≥33% relative growth on follow-up CT within 24 hours — occurs in 25–40% of patients and is the single most modifiable contributor to mortality and disability. Identifying patients at high risk of expansion at presentation enables targeted aggressive blood-pressure control, anticoagulant reversal, and surgical planning.

The CTA spot sign

On a CT angiogram performed within 6 hours of onset, the spot sign is a focus of contrast extravasation seen as a hyperdense (≥120 HU) dot or serpiginous focus inside the hematoma, discontinuous from any normal vessel, with shape and size that vary across the arterial and delayed venous phases (when multiphase CTA is performed). Spot sign sensitivity for expansion is 50–60%, specificity is 80–90%, positive predictive value approximately 60%.

Spot sign criterionDetail
LocationWithin the hematoma, not at the periphery touching a vessel
Density≥120 HU (markedly hyperdense to surrounding clot)
Shape/size1.5 mm to several mm; round, oval, or serpiginous
ContinuityDiscontinuous from any normal arterial or venous structure
Number1–5+ spots; greater number = higher expansion risk
Multiphase progressionIncreases in size/density on delayed phases (venous/late) — most specific for active extravasation

Non-contrast CT expansion predictors (no CTA available)

SignDefinitionPredictive value
Irregular shapeHematoma not a smooth ellipsoid; categorical scale 1–5 (5 = highly irregular)OR for expansion ~2.5; categories 4–5 are highest risk
Swirl signHypodense or isodense region inside an otherwise hyperdense hematomaSuggests active oozing; OR for expansion ~3
Black hole signEncapsulated hypoattenuating area inside hyperdense hematoma; sharp border; ≥28 HU lower than parent hematomaSensitivity ~30%, specificity ~95%
Blend signTwo distinct attenuation regions within hematoma with a clear blending interface; ≥18 HU differenceSensitivity ~40%, specificity ~95%
Satellite signSmall (1–10 mm) hematoma separate from the parent hematoma but in the same anatomical regionSensitivity ~60%, specificity ~70%
Island sign≥3 scattered small hematomas separate from the main bleed, or ≥4 small hematomas connected to the main oneSensitivity ~30%, specificity ~95%
Hypodensity signAny hypoattenuating region within the hematoma (umbrella term)Sensitivity ~70%, specificity ~70%
Practical translation: A patient with spot sign positive, irregular shape, blend or swirl sign, and presentation within 6 hours has >60% probability of significant expansion. Target SBP <140 mmHg with IV labetalol or nicardipine within 1 hour, reverse any anticoagulant aggressively (4-factor PCC + vitamin K for warfarin; idarucizumab for dabigatran; andexanet alfa or 4F-PCC for FXa inhibitors), and request a 6-hour repeat CT.
Hematoma expansion risk-stratified workflow Decision pathway from non-contrast CT through CTA to expansion-targeted intervention Hematoma Expansion Workflow Acute ICH on NCCT Within 6h of onset, GCS >5 CTA spot sign + expansion signs? NEGATIVE — low expansion risk SBP target 140 mmHg Standard ICU monitoring Repeat CT at 24h Reverse anticoagulant if any POSITIVE — high expansion risk Aggressive SBP <140 within 1h Reverse anticoagulant URGENT Repeat CT at 6h Surgical consult if expanding
Figure 1. Expansion-targeted workflow. The CTA spot sign and non-contrast CT expansion signs (irregular shape, swirl, blend, black hole, satellite, island) identify the 25–40% of patients in whom the next 6 hours determine outcome.

S4Etiology by Location & Pattern

Anatomical location is the strongest single predictor of etiology. Hypertensive bleeds favor the deep perforator territories (basal ganglia, thalamus, pons, deep cerebellum). Cerebral amyloid angiopathy (CAA) favors the cortex/subcortical lobar regions. Secondary causes — vascular malformation, tumor, venous thrombosis, vasculitis, sympathomimetic drug — vary widely but cluster in patterns that the imager must recognize.

Location–etiology probability map

LocationProbable etiologyImaging follow-up
Putamen, globus pallidus, internal capsuleHypertensive (deep perforators of MCA)None unless <55 yr or atypical features
ThalamusHypertensive; secondary venous infarct (vein of Galen, internal cerebral vein) if bilateral or symmetricCTV or MRV if bilateral thalamic ICH
PonsHypertensive (paramedian perforators of basilar)None unless atypical features; outcomes generally poor
Cerebellar hemisphereHypertensive (PICA, AICA, SCA territories)None unless <55 yr; surgical urgency if >3 cm
Lobar (cortical/subcortical, parietal/occipital)Cerebral amyloid angiopathy in elderly; AVM/cavernoma in young; tumor; venous thrombosisMRI with GRE/SWI for microbleeds + superficial siderosis (CAA); CTA/MRA for AVM
MultifocalCAA, vasculitis, septic emboli, hemorrhagic metastases, anticoagulant overdoseMRI with contrast + GRE/SWI; CTA; LP if vasculitis suspected
Subarachnoid + parenchymalAneurysmal SAH with parenchymal extension; AVM; traumaCTA emergent; consider DSA
Bilateral parasagittal frontalCerebral venous sinus thrombosis (superior sagittal sinus)CTV emergent

Indications for CT angiography (vascular workup)

  • Age <55 years (lower likelihood of hypertensive cause; higher likelihood of AVM, aneurysm, cavernoma)
  • Lobar hemorrhage (rule out AVM, aneurysm, dural fistula, tumor)
  • Atypical location (pure intraventricular, isolated SAH-like pattern, thalamic-IVE pattern)
  • Suspicious clinical history (sudden onset, thunderclap headache, new seizure, history of vascular malformation)
  • Multiple or recurrent hemorrhages
  • Patient otherwise a candidate for hematoma evacuation (vascular cause changes operative approach)
  • Spot sign assessment in any candidate for aggressive expansion-prevention therapy

MRI indications

SequenceIndicationFinding
GRE/SWISuspect cerebral amyloid angiopathy in elderly with lobar bleedMultiple cortical/subcortical microbleeds; superficial siderosis
FLAIRSubacute ICH (1–3 weeks) when CT becomes isodenseHyperintense ring with hypointense center; perilesional edema
Post-contrast T1Suspect underlying tumor (hemorrhagic metastasis or primary)Enhancement that does not match expected blood-product evolution
MRA TOFAVM, aneurysm without CTA contrast optionTangle of vessels (AVM); saccular outpouching (aneurysm)
MRVSuspect cerebral venous sinus thrombosisAbsent flow signal in dural sinus or deep venous system

S5ICH Score & Surgical Thresholds

The ICH score (Hemphill et al., 2001) integrates five variables — GCS, age, hematoma volume, infratentorial location, and intraventricular extension — to predict 30-day mortality. It is the operational stratification tool every neuro-ICU and neurosurgery service uses.

ICH score components

VariablePoints
GCS 13–150
GCS 5–121
GCS 3–42
Age ≥80 yr1
Hematoma volume ≥30 cm³1
Infratentorial origin1
Intraventricular extension1
Total range0–6

ICH score → 30-day mortality

Score30-day mortality
00%
113%
226%
372%
497%
5–6100%

Surgical evacuation indications (AHA/ASA 2022)

IndicationRecommendation strength
Cerebellar ICH >3 cm with neurological deterioration, brainstem compression, or hydrocephalus from ventricular obstructionClass I — emergent posterior fossa craniectomy is life-saving
Supratentorial ICH with deteriorating GCS, mass effect, or refractory ICP elevationClass IIb — minimally invasive evacuation (MISTIE/ENRICH approach) reasonable for moderate-volume bleeds in selected patients
Standard open craniotomy for supratentorial ICHClass IIb — limited routine benefit (STICH I + II); reserved for life-threatening mass effect
Intraventricular hemorrhage with hydrocephalusClass I — external ventricular drain for ICP control and clearance; intraventricular alteplase (CLEAR III) reduces IVH volume but has not improved functional outcome
Underlying AVM, aneurysm, or cavernomaClass I — definitive treatment of vascular lesion (clipping, coiling, resection, radiosurgery)
When to call neurosurgery (urgent):
  • Cerebellar hemorrhage >3 cm or with brainstem compression / 4th ventricle obliteration / hydrocephalus
  • Lobar hemorrhage >30 cm³ in a previously functional patient with deteriorating GCS
  • Intraventricular hemorrhage with hydrocephalus (EVD candidate)
  • Hematoma expansion ≥6 cm³ on serial CT despite optimal medical therapy
  • Underlying vascular lesion identified on CTA (AVM, aneurysm, dural AV fistula)
  • Posterior fossa hematoma of any size with declining GCS

Blood pressure target — ATACH-2 / INTERACT3 evidence

Aggressive blood-pressure lowering to SBP <140 mmHg within 1 hour of presentation is safe and reduces hematoma growth in ATACH-2 and INTERACT3, but did not improve functional outcome at 90 days in either trial individually. INTERACT3’s care bundle — early intensive BP control + glucose control + temperature control + anticoagulation reversal — improved functional outcome (mRS) at 6 months. Operational target: SBP 130–140 mmHg within 1 hour, sustained for 24 hours, with IV nicardipine, labetalol, or clevidipine; avoid SBP <110 mmHg (associated with renal injury and worse outcome).

S6Pearls, Pitfalls & FAQ

Pearl

ABC/2 takes 30 seconds at the bedside and is ≥95% as accurate as planimetric volumetry for hematomas of moderate size and regular shape. Use it on every CT, document the volume in the radiology report, and use the same method for serial measurements to track expansion (do not switch methods mid-course).

Pitfall

The CTA spot sign is a 6-hour window phenomenon — its sensitivity drops sharply after 6 hours from onset. CTA performed too late will produce false negatives. Confirm the time of onset before relying on a negative spot sign to de-escalate management.

Pearl

Lobar hemorrhage in an elderly patient (≥70 yr) with multiple cortical microbleeds and superficial siderosis on MRI GRE/SWI is cerebral amyloid angiopathy until proven otherwise. The recurrence risk is >10% per year; avoid antiplatelet/anticoagulant therapy and counsel on rebleed risk. Boston criteria 2.0 stratify diagnostic certainty.

Pitfall

Bilateral thalamic hemorrhage or symmetric deep gray matter hemorrhage suggests cerebral venous sinus thrombosis (deep venous system involvement) — not hypertensive ICH. Order CTV or MRV emergently. Failure to recognize this pattern delays anticoagulation and converts a treatable disease into a fatal one.

Pearl

Cerebellar hematoma >3 cm or any cerebellar bleed with deteriorating GCS is a neurosurgical emergency — posterior fossa craniectomy is life-saving and improves outcome dramatically. Do not be fooled by a relatively preserved GCS at presentation; brainstem compression can develop in hours.

Pitfall

Anemic patients (Hgb <9 g/dL) have lower hematoma density (35–55 HU instead of 50–80 HU). Small bleeds may be missed or mistaken for tumor. Always interpret CT density in the context of the patient’s hemoglobin.

FAQ

How accurate is the ABC/2 formula for hematoma volume estimation?
ABC/2 was validated in the original 1996 Kothari paper against planimetric volumetry with R² ≈ 0.96 in moderate, regularly shaped hematomas. It underestimates by ~10–20% in irregularly shaped hematomas (which is the shape that predicts expansion) and overestimates in small bleeds <10 cm³. For routine bedside use it is excellent. For surgical decision-making in marginal cases (e.g., volume estimate at the 30 cm³ threshold), request planimetric segmentation from the radiologist or AI tool.
When does the spot sign add the most value?
The spot sign is most useful within the first 6 hours of onset, when CTA can be performed in time to capture active extravasation, and in moderate-volume hematomas (10–60 cm³) where the question of expansion is operationally relevant. A positive spot sign in a patient at 4 hours from onset with a 25 cm³ basal ganglia bleed mandates aggressive SBP <140 mmHg, urgent reversal of any anticoagulant, and a 6-hour repeat CT. A positive spot sign at 12 hours is less informative because the high-risk expansion window is closing.
Does aggressive blood-pressure lowering improve functional outcome in ICH?
Aggressive lowering to SBP 130–140 mmHg within 1 hour is safe and reduces hematoma expansion in ATACH-2 and INTERACT3 individually. Neither trial individually demonstrated functional outcome improvement at 90 days (modified Rankin Scale). However, INTERACT3’s care bundle — early intensive BP control plus glucose control plus temperature control plus anticoagulant reversal — significantly improved functional outcome at 6 months. The current AHA/ASA 2022 guideline therefore recommends aggressive early BP lowering to SBP 130–140 mmHg as part of a multi-modal bundle, sustained for the first 24 hours, avoiding SBP <110 mmHg.
When should I order an MRI in addition to CT?
Order MRI when (1) the patient has lobar hemorrhage and is age ≥55 — GRE/SWI sequences identify cortical microbleeds and superficial siderosis diagnostic of cerebral amyloid angiopathy; (2) the bleed is in an atypical location or pattern suggesting underlying tumor or vascular lesion — post-contrast T1 identifies enhancing components; (3) you encounter a subacute hematoma (1–3 weeks) that has become isodense on CT — FLAIR and T2 reveal the bleed unmistakably; (4) cerebral venous sinus thrombosis is suspected — MRV without contrast or with contrast clarifies sinus patency. MRI is rarely needed in the hyperacute (0–6 h) decision window — non-contrast CT plus CTA suffices.
When is surgical hematoma evacuation indicated?
Cerebellar hematoma >3 cm with brainstem compression, 4th-ventricle obstruction, or hydrocephalus is an absolute Class I indication for emergent posterior fossa craniectomy — outcomes are dramatically better with surgery than medical management. For supratentorial hematomas, open craniotomy has been disappointing in randomized trials (STICH I and II showed no overall benefit). Minimally invasive evacuation (MISTIE III, ENRICH) shows benefit in selected patients with moderate-volume lobar or deep bleeds and is a Class IIb recommendation. Intraventricular hemorrhage with hydrocephalus warrants EVD placement (Class I) for ICP control. Underlying AVM, aneurysm, or cavernoma identified on CTA mandates definitive vascular treatment.

Practice Insights: Lessons from ED and Neuro-ICU Bedside CT Interpretation

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)A hematoma measured once and never remeasured is the standing risk in intracerebral hemorrhage, where growth happens quietly, and it follows that the first 24-hour window is where prognosis is determined, and that the radiology read in the chart is often hours behind the bedside-team decision. The four patterns experienced practice tracks most carefully are the chronic ABC/2 miscalculation that distorts ICH-score risk stratification, the unrecognized non-contrast expansion markers (heterogeneous density, swirl, island, blend, black-hole signs) that flag patients needing repeat imaging without waiting for CTA, the spot-sign-positive patient who needs aggressive blood-pressure control and early re-scan, and the location-pattern shorthand that immediately separates hypertensive from amyloid from vascular-malformation etiology.

ICH CT: ABC/2 Calculation, Non-Contrast Expansion Signs, Spot Sign Triage, and Location-Based Etiology Four-panel matrix showing ABC/2 volume calculation method, non-contrast CT signs that predict hematoma expansion, spot sign management pathway with BP target, and ICH location-to-etiology mapping. ICH CT: Four Bedside Anchors in the First 24 Hours ① ABC/2 Volume — Calculate, Don’t Eyeball V (mL) = A × B × C ÷ 2 All measurements in centimeters Definitions: ▸ A: largest diameter on axial slice ▸ B: perpendicular diameter, same slice ▸ C: slices showing hematoma × slice thickness Threshold table: ▸ < 30 mL: ICH score 0; better surgical option pool ▸ ≥ 30 mL: 1 point on ICH score; worse outcomes ② Non-Contrast Expansion Markers Heterogeneous density: mixed hyper- and hypodense regions Island sign: ≥3 separate small density islands Swirl sign: hypodense area within hyperdense clot Blend sign: hypodense + hyperdense in juxtaposition Black-hole sign: round hypodensity within hematoma Any one → expect ≥ 33% expansion in 24 h Repeat CT at 4–6 h regardless of CTA availability ③ Spot Sign → Aggressive Management CTA Spot Sign Positive Contrast extravasation focus within hematoma ~50% expand vs ~10% (negative) ▸ SBP target < 140 mmHg (INTERACT-2) ▸ Repeat non-contrast CT at 4–6 h ▸ Reverse coagulopathy (PCC, vit K, idarucizumab) ▸ Neurosurgery consult for monitoring/EVD Don’t anticoag reversal: rapid TXA is being studied ④ Location → Etiology Pattern Location Likely etiology Basal ganglia, thalamus Hypertensive (90%) Lobar — elderly CAA > HTN Lobar — young AVM, cavernoma — CTA/MRI Pons Hypertensive (high mortality) Cerebellum Hypertensive — surgical Multi-focal, age < 50 CVST, vasculitis — MRV + IVH extension +1 ICH score; consider EVD Lobar < 50 yo or unusual pattern = vessel workup

1. Calculate the ABC/2 Volume — Do Not Estimate

The single most common preventable error experienced clinicians correct on bedside review is eyeball volume estimation. In experienced practice every ICH gets a measured ABC/2 calculation before any treatment decision: largest axial diameter, perpendicular diameter on the same slice, and the number of slices showing hematoma times the slice thickness — divided by two for the ellipsoid approximation. The 30 mL threshold is a hard cut-point on the ICH score and an inflection on the surgical-candidacy curve, and in experienced hands a 28 mL hematoma that gets labelled “about 40 mL” misroutes the patient toward worse counseling and unnecessary surgical discussion.

2. Non-Contrast Expansion Signs Flag the Patient Who Needs the 4-Hour Re-Scan

Experienced clinicians have established not to wait for CTA availability to identify the expansion-risk patient. In practice any of the non-contrast markers — heterogeneous density, island sign (≥3 small density islands), swirl sign (hypodense within hyperdense), blend sign, black-hole sign — earns a planned repeat non-contrast CT at 4 to 6 hours and aggressive blood-pressure management to systolic 130–140 mmHg in the interval. These signs have moderate to high specificity for ≥33% expansion in the next 24 hours, and in centers where CTA is delayed or contraindicated, they are the bedside tool that matters.

3. A Positive Spot Sign Reorganizes the First Six Hours

The CTA spot sign is the single highest-yield acute finding in experienced practice. A positive spot sign — focal contrast extravasation within the hematoma on CTA — predicts roughly 50% expansion in the next 24 hours compared with about 10% for spot-sign-negative hematomas. In practice a spot-sign-positive patient gets a hard systolic blood pressure target below 140 mmHg (INTERACT-2 informed), urgent coagulopathy reversal if applicable (4-factor PCC for warfarin, idarucizumab for dabigatran, andexanet alfa for apixaban/rivaroxaban with caveats), a planned 4-hour repeat CT, and a neurosurgical consult with low threshold for external ventricular drainage if intraventricular extension is present. The negative spot sign permits a less aggressive surveillance posture but does not exclude expansion.

4. Location Is Etiology Shorthand — Especially Under 50

Experienced clinicians have learned to think of location as the first-pass etiology filter. Deep basal ganglia or thalamic hemorrhage in an older hypertensive patient is hypertensive bleed until proven otherwise; lobar hemorrhage in an elderly patient should raise cerebral amyloid angiopathy, especially with prior microbleeds on MRI gradient echo. The critical decision in practice is the lobar hemorrhage in a patient under 50, which mandates vessel imaging (CTA initially, MRA or DSA if necessary) to exclude arteriovenous malformation, cavernoma, dural arteriovenous fistula, or aneurysm. Experienced practice would rather order a CTA on the first day and not need it than discover an AVM on the post-discharge clinic MRI.

Illustrative Scenario

A patient in their seventies on warfarin for atrial fibrillation presented with sudden right hemiparesis, dysarthria, and a Glasgow Coma Scale of 12. INR on arrival was 2.6. Initial non-contrast CT showed a left putaminal hematoma. The radiology preliminary read estimated “approximately 45 mL” of hematoma. On bedside ABC/2 calculation using the dictation room workstation the treating clinicians measured A = 4.2 cm, B = 2.4 cm, and C = 3 cm (six axial slices of hematoma at 0.5 cm thickness), giving a measured volume of 15.1 mL — not 45 mL. The hematoma had heterogeneous density with a discrete hypodense focus suggestive of a swirl sign.

The ICH score was recalculated using the correct volume (ICH score 1 instead of 2 from the eyeball estimate), and the family counseling and surgical-team discussion shifted accordingly. Given the swirl sign and warfarin coagulopathy, the treating clinicians started 4-factor prothrombin complex concentrate immediately, intravenous vitamin K, and titrated nicardipine to a systolic target of 130–140 mmHg. CTA was performed and was spot-sign negative; planned repeat non-contrast CT at five hours showed stable hematoma. The patient was admitted to neuro-ICU, mobilized at day three after stable serial imaging, and discharged to inpatient rehabilitation with a modified Rankin Scale of 3 at six weeks.

Takeaway: A measured ABC/2 reclassified the patient’s prognostic tier and the family’s goals-of-care conversation. The volume number drives more downstream decisions than any other CT finding.

the established Standing Protocol Adjustments

  1. Measure ABC/2 volume on every ICH before any treatment decision or family discussion; document the calculation in the chart and never accept an eyeballed estimate for ICH-score risk stratification.
  2. Read for non-contrast expansion markers on every initial scan: heterogeneous density, island sign, swirl sign, blend sign, black-hole sign — any one earns a planned 4–6 hour repeat CT and SBP target 130–140 mmHg in the interval.
  3. Treat a positive CTA spot sign as an emergency expansion phenotype: hard SBP < 140 mmHg, immediate coagulopathy reversal where indicated (4-factor PCC for warfarin, idarucizumab for dabigatran, andexanet alfa for factor-Xa inhibitors), planned 4-hour repeat CT, low-threshold neurosurgery consult.
  4. Order vessel imaging (CTA at minimum) for any lobar ICH in a patient under 50, or any pattern that does not fit hypertensive or amyloid distribution; consider MRA/MRV and DSA for negative CTA in young patients to exclude AVM, dural AVF, or CVST.
GUIDELINE REFERENCES

Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.

Leave a Reply

Your email address will not be published. Required fields are marked *